tion. The purpose of this report was to compare HIV-infected patients who had PH with non-HIV-infected patients who had primary pulmonary hypertension (PPH) in terms of (1) clinical characteristics, (2) hemodynamics in baseline conditions and during a short-term vasodilator trial with epoprostenol, and (3) survival.
Methods and Results Between April 1987 and August 1992, 20 HIV-infected patients with PH and 93 non-HIV-infected patients with PPH were referred to our department. At the time of referral, baseline right-side heart hemodynamics were obtained in addition to demographic variables and medical history. A short-term vasodilator trial with epoprostenol was performed in 19 of 20 HIV-infected and 86 of 93 non-HIVinfected patients. Outcome and survival were analyzed and compared for both groups (22 transplant recipients were excluded from the group of patients with PPH). At the time of diagnosis of PH, HIV-infected patients significantly differed from non-HIV-infected patients in age (32±5 versus 42±13 years; P<.05) and degree of disability (New York Heart Association functional class III or IV, 50% versus 75%; P<.01). The proportion of disease states known to be associ- Originally submitted to La Jolla, Calif. ated with PPH (Raynaud's phenomenon, migraine, collagen disease without overt symptoms and signs, or a positive family history of PPH) was similar in the two groups. HIV-infected patients had a severe but significantly lower level of PH than patients with PPH. The percentage of responders to epoprostenol and the level achieved in pulmonary vasodilatation were similar in the two groups. PH was the cause of death in 8 of the 10 HIV-infected patients who died within 1 year after the diagnosis of PH. Overall survival was poor and not significantly different between the two groups. Pathological findings in lung tissue obtained from 3 HIV-infected patients were close to those seen in most of the lung specimens available from 27 patients with PPH and resembled plexogenic pulmonary arteriopathy.
Conclusions These results support the view that HIV infection may now be regarded as another common disease state that can be associated with PPH development. The lower initial severity in HIV-infected patients may be due to the close medical attention usually devoted to such patients, who may account for an earlier diagnosis. However, the overall survival rate of HIV-infected patients with PH appeared to be as poor as in non-HIV-infected patients with PPH. (Circulation. 1994;89:2722-2727.)
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Methods

Patients
The diagnosis of PPH was established by the results of right-side heart catheterization (the presence of elevated mean pulmonary artery pressure >25 mm Hg and normal pulmonary wedge pressure) and after exclusion of potential causes of secondary PH according to the diagnostic criteria of the National Institutes of Health Registry on PPH. 13 Patients with portal hypertension and/or cirrhosis were excluded, although there is debate as to whether this association disqualifies a patient from the diagnosis of PPH.
For each HIV-infected patient with PH, complete clinical information with follow-up to September 1992 was obtained by reviewing hospital and referring physician medical records, including age, sex, HIV risk factors, time between the discovery of HIV positivity and diagnosis of PH, staging of HIV infection according to the Centers for Disease Control and Prevention (CDC) classification, length of survival, and cause of death. Considering HIV risk factors, particular attention was paid to drug addiction (duration, route of administration, and type of drugs), especially seeking a history of injection of solutions derived from pills or tablets intended for oral use. At the time of diagnosis of PH, laboratory studies included routine blood tests, serum antibodies to HIV, HIV P24 antigenemia, and blood CD4+ T-lymphocyte count.
For the overall population, a complete clinical evaluation was conducted, including onset of symptoms, degree of disability assessed by the New York Heart Association (NYHA) functional classification, syncope or near syncope, chest pain, and right-side heart failure. Attention was also paid to the following clinical conditions commonly recognized to be associated with PPH13: isolated Raynaud's phenomenon, migraine, a positive family history of PPH, and significant serum antinuclear antibody (ANA) titers (>1/80).
Hemodynamic Study
For each patient, all vasodilator or inotropic drugs previously administered were withdrawn at least 36 to 48 hours before catheterization. Central venous access was achieved through an antecubital vein (in most patients) or through an internal jugular vein. Right-side heart catheterization was performed under fluoroscopic guidance with a 7F triple-lumen flow-directed thermodilution catheter (Swan Ganz, BaxterEdwards) with the tip positioned in a branch of a lower pulmonary artery. All parameters were then obtained in an intensive care unit in the patients supine, at rest, and breathing room air. Heart rate was monitored continuously. Systemic arterial pressure was measured intermittently by an external automated blood pressure cuff (Dinamap, Critikon).
Cardiac output (CO) was measured by the thermodilution technique (frozen saline) and calculated as the mean value of at least three consecutive injections. Cardiac index (CI) was calculated as CO per squared meter of body surface area. Because the pulmonary artery wedge pressure could not be consistently recorded during the entire hemodynamic study in many patients, the total pulmonary vascular resistance (TPR) (instead of the pulmonary arteriolar resistance) was calculated as mean pulmonary artery pressure divided by CI.
A mean of three sets of baseline hemodynamic measurements was obtained in each patient to appreciate the individual spontaneous hemodynamic variability. Then, a short-term vasodilator trial with epoprostenol (prostacyclin, Flolan, Wellcome) was performed in most patients. Epoprostenol is considered to be a sensitive screening agent in detecting the capacity to acutely vasodilate the pulmonary vasculature in patients with PPH.1415 Epoprostenol was infused continuously in a peripheral vein with the dosage increased at increments of 2.5 ng* kg.* min1 every 10 minutes from 2.5 ng* kg.* min1 to a maximal dosage of 10 ng . kg-1 min-m. The infusion was stopped immediately if systemic blood pressure decreased by more than 30% or if the heart rate increased by more than 50% compared with control values and/or if side effects precluded an increase in dosage. A significant individual vasodilator response was defined as a decrease in TPR of >20% compared with mean TPR baseline value. Subsequently, but only in significant responders to prostacyclin, other drugs (isoproterenol, nitroglycerin, phentolamine, diltiazem, and hydralazine) were tested intravenously to select the optimal agent that can be taken orally to maintain pulmonary vasodilatation chronically in combination with oral anticoagulant therapy. Only the results of the short-term testing with epoprostenol will be discussed further.
Statistical Analysis
Values are given as mean+SD. Comparisons of selected variables were made using statistical methods including the Student's t test and V2 test, where appropriate. Because the sample size of the HIV-infected group was small, all continuous variables were retested with the nonparametric method of the Wilcoxon rank-sum test to confirm differences that were considered to be significant. Survival was estimated from first catheterization in our hospital until the end of the follow-up period (date of most recent information on the patient or death) by the Kaplan-Meier product-limit method. Lung or heart-lung transplant recipients in the PPH estimated incidence (0.02%) of PPH in the general population. 16 Some disease states are known to be associated with PPH development, such as isolated Raynaud's phenomenon, migraine, collagen disease without overt symptoms or signs, and a positive family history of PPH. 13, 17 The proportion of such clinical conditions was similar in our two patient populations, suggesting that PH had arisen in equally "susceptible" patients. A female-tomale predominance is well known in PPH13'1618 and was also found in our HIV-infected patients, even though evident sexual bias usually leads to a male predominance in the general distribution of HIV risk factors (eg, hemophiliacs, homosexuals).
Hemodynamic changes observed during a short-term vasodilator trial with epoprostenol were quite similar in both groups, providing further argument that they may suffer from the same pulmonary vascular disease. This can also be supported by the close pathological changes observed in the pulmonary vasculature of our HIVinfected and non-HIV-infected patients, in keeping with findings previously reported in the literature. 3, 6, 8 The first major report of PH associated with HIV infection concerned only patients with classic hemophilia, raising questions about a cause-and-effect relation between PH and the use of factor VIII concentrates of low purity.2 Since then, it has been shown that PH may develop in HIV-infected patients regardless of the degree of immunosuppression and/or risk factor. Photomicrograph of pathological findings in lung tissue obtained from an HIV-infected patient with a history of long-term intravenous heroin abuse (patient 20; see Table 1) , showing a typical plexiform lesion. There was no evidence for associated intravascular and/or interstitial foreign body granulomas (hematoxylin eosin saffron, x 160).
pathological finding in such a condition'9 and is believed to be due to foreign particle pulmonary emboli following injections of solutions derived from tablets or pills containing insoluble microcrystals.19 Ordinary heroin does not contain enough crystalline debris to induce extensive pulmonary angiothrombosis,'9 and because fewer than 5% of drug addicts frequently inject tablet derivatives,20'22 PH is supposed to be rare among them. This was confirmed in the late 1970s before HIV infection was epidemic.23 Repeated injections of foreign particles were denied by all of our drug addicts. Moreover, lung pathological specimens obtained from 4 HIV-infected drug abusers with PH reported in the literature3 6 8 did not show any foreign body granulomas (like in our patients 4 and 20) (Fig 2) .
HIV-infected and non-HIV-infected patients differed significantly in age, functional class, and initial hemodynamic severity (Tables 2 and 3 ). This may be explained, as well as the shorter time interval between onset of symptoms and diagnosis of PH, by the close medical attention usually devoted to HIV-infected patients who may account for an earlier diagnosis, although both conditions were simultaneously diagnosed in 5 of the 20 patients reported here.
Survival in PPH is known to be poor24 and has been reported to be limited as well in HIV-infected patients with PH. 1-3 5-9 Survival in our HIV-infected patients was not significantly different than that in patients with PPH who had been evaluated and treated in the same manner. However, considering that HIV-infected patients had a shorter average duration of symptoms attributable to PH before initial catheterization, a faster disease evolution in HlV-infected patients cannot be ruled out.
The pathogenesis of the pulmonary arterial disease associated with HIV infection is unknown, as it is in PPH. 17 The hypothesis of a direct impact of the virus on the pulmonary vascular smooth muscle and/or endothelial cells has not been demonstrated.12 An indirect role of HIV in the production of growth factors leading to abnormal endothelial and smooth muscle cell proliferation has also been discussed.7 In conclusion, the clinical, hemodynamic, and pathological similarities between HIV-infected patients with PH and non-HIV-infected patients with PPH suggest that HIV infection must be regarded as another common risk factor for PPH development. Subsequently, it seems reasonable to routinely perform HIV tests in patients presenting with PPH. Finally, this likely association obviously raises the question of a viral involvement in the pathogenesis of PPH in general.
